Prelude Therapeutics Inc

Research Prelude Therapeutics Inc (PRLD) on Bullrun: market cap USD 392.65M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerPRLD
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 392.65M
• Financial periodFY2025
• RevenueUSD 12.14M
• Revenue growth73.4%
• Net income-USD 99.50M
• Free cash flow-USD 56.37M

Valuation Snapshot

latest market cap is USD 392.65M.

About Prelude Therapeutics Inc

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.

Frequently asked questions

What is Prelude Therapeutics Inc's market cap?

Prelude Therapeutics Inc's market capitalization is USD 392.65M.

What does Prelude Therapeutics Inc do?

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.